Sulforaphane is produced by glucoraphanin under the catalysis of myrosinase in crushed cruciferous plants and is well known for its anti-inflammatory, bacteriostatic and functions. Researches have shown that microorganisms could convert glucoraphanin into sulforaphane in human body and natural environment. However, the transformation efficiency of sulforaphane by intestinal microorganisms is not sufficient. In order to improve human health, this research focused on screening and delivering probiotics with high sulforaphane transformation efficiency into human body and promoting probiotics to produce more sulforaphane. In this research, microorganisms capable of transforming sulforaphane in nature were screened, identified, and further delivered to intestine through a microbe-targeted delivery system (thiolated oxidized konjac glucomannan, sOKGM) to improve the in vivo transformation efficiency of sulforaphane. The results showed that the sulforaphane was converted from glucoraphanin with higher transformation rate of 0.1863 × 10−4 mol h−1 logCFU−1 in Lactobacillus plantarum than that of L. acidophilus and L. paracasei. In addition, the encapsulation efficiency of L. plantarum by microbe-targeted delivery system was 87.02%, with the survival rate of 28.33%. The sulforaphane content of embedded L. plantarum group was 3.075 × 10−3 mol L−1, which was significantly higher than that of not embedded L. plantarum group (1.430 × 10−3 mol L−1) after digestion with simulated gastrointestinal fluid. This research revealed that L. plantarum could effectively improve the transformation efficiency of sulforaphane in human intestines, providing strong experimental evidence to support the high-value utilization of sulforaphane and enhancement of human health.
Read full abstract